Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Drug ID: DAP000192

Drug Information
SynonymsAdriamycin semiquinone; Doxorubicine [INN-French]; LMPK13050001; Adriamycin RDF (hydrochloride salt); EINECS 245-495-6; Aerosolized Doxorubicin; Adriacin (hydrochloride salt); Prestwick3_000438; Prestwick0_000438; 14-Hydroxydaunorubicine; Probes2_000129; CHEMBL179; MLS000759533; Hydroxydaunomycin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; D03899; ThermoDox; Doxorubicin citrate; 23257-17-2; Doxorubicin-P4/D10 conjugate; 111266-55-8; 25316-40-9 (hydrochloride); NChemBio.2007.10-comp13; 24385-08-8; Prestwick1_000438; Adriblastina (TN); ADM; adriablatina (hydrochloride salt); LS-165655; NDC 38242-874; CHEBI:28748; CCRIS 739; Doxorubicina [INN-Spanish]; Triferric doxorubicin; DOX-SL; FI 106; DB00997; BSPBio_001031; Probes1_000151; Myocet; SPBio_002395; TLC D-99; Prestwick2_000438; LS-1029; Doxorubicin hydrochloride (hydrochloride salt); Adriablastin; CID31703; Doxorubicin-P4/D10; NCI-C01514; RDF Rubex; Doxorubicin-hLL1 conjugate; adriablastine (hydrochloride salt); Doxorubicin (USAN/INN); Doxorubicinum [INN-Latin]; NSC 123127; Adriblastin; Adriblas tina; 25311-50-6; Doxil; 25316-40-9; AC1L1M5T; Farmablastina (hydrochloride salt); 29042-30-6; Adriamycin PFS (hydrochloride salt); Doxorubicin [USAN:INN:BAN]; adr iablatina (hydrochloride salt); C01661; Adriblastina (hydrochloride salt); JT9100000; DM2; Doxorubicine; Rubex (hydrochloride salt); Adriamycin RDF; BSPBio_000456; BPBio1_000502; Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Doxorubicin Hydrochloride; AC1Q29OJ; Doxorubicina; Resmycin; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; nchembio809-comp5; 14-Hydroxydaunomycin; Adriamycin; 23214-92-8; HSDB 3070; Rubex; UNII-80168379AG; NIOSH/JT9100000; Adriblastina; doxorubicin; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; adriblatina (hydrochloride salt); Adriamycin PFS; C27H29NO11; SMP1_000106; ADR; Hydroxydaunorubicin hydrochloride (hydrochloride salt); adiblastine (hydrochloride salt); BRD-K92093830-003-04-3; Doxorubicinum; HMS2089H06
Trade NameAdriamycin PFS; Adriamycin RDF; Rubex; Caelyx; Myocet
CompanySequus Pharmaceuticals Inc
[ICD9: 140-229   ICD10: C00-C96]
Approved    [1]

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
Canonical SMILESCC1C(C(CC(O1)OC2CC(CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)
Isomeric SMILESC[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 23214-92-8
PubChem Compound IDCID 31703.
PubChem Substance IDSID 4809.
SuperDrug ATC IDL01DB01
SuperDrug CAS ID023214928;
TargetDNA topoisomerase IIInhibitor[2][3]
Ref 1Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. To Reference
Ref 2NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform. J Biol Chem. 2008 Aug 29;283(35):23711-20. Epub 2008 Jul 2. To Reference
Ref 3Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res. 2000 May 1;60(9):2429-34. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543